Clinical trial
Phase I Study of Patupilone and RAD001
NCT00496600 · University of Medicine and Dentistry of New Jersey, Other · Completed
Key facts
| NCT number | NCT00496600 |
|---|---|
| Title | Phase I Study of Patupilone and RAD001 |
| Official title | Phase I Study of Patupilone and RAD001 in Patients With Refractory Solid Tumor Malignancy |
| Lead sponsor | University of Medicine and Dentistry of New Jersey, Other |
| Collaborators | Novartis Pharmaceuticals Industry National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Refractory Malignancy |
| Intervention type | Drug |
| Interventions | Patupilone, RAD001 |
| Enrollment | 42 |
| Start date | Jul 1, 2007 |
| Primary completion | Feb 1, 2011 |
| Completion | Feb 1, 2011 |
| First posted | Jul 4, 2007 |
| Last update posted | Jun 14, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: